BioLineRx Historical Income Statement
| BLRX Stock | USD 0.32 0.23 41.82% |
Historical analysis of BioLineRx income statement accounts such as Interest Expense of 2.3 M, Selling General Administrative of 17.5 M or Selling And Marketing Expenses of 15.3 M can show how well BioLineRx performed in making a profits. Evaluating BioLineRx income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioLineRx's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining BioLineRx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioLineRx is a good buy for the upcoming year.
BioLineRx |
About BioLineRx Income Statement Analysis
BioLineRx Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioLineRx shareholders. The income statement also shows BioLineRx investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
BioLineRx Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioLineRx. It is also known as BioLineRx overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from BioLineRx's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioLineRx current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.At this time, BioLineRx's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 2.3 M in 2024, whereas Total Revenue is likely to drop slightly above 4.6 M in 2024.
BioLineRx income statement Correlations
Click cells to compare fundamentals
BioLineRx Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioLineRx income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.2M | 934K | 702K | 654K | 1.4M | 1.5M | |
| Interest Expense | 1.8M | 1.5M | 984K | 2.2M | 2.2M | 2.3M | |
| Selling General Administrative | 3.7M | 3.8M | 4.3M | 5.1M | 16.6M | 17.5M | |
| Selling And Marketing Expenses | 1.4M | 857K | 840K | 6.5M | 14.6M | 15.3M | |
| Gross Profit | (940K) | (934K) | (702K) | (654K) | 1.1M | 1.1M | |
| Other Operating Expenses | 28.1M | 22.9M | 24.8M | 29.2M | 54.5M | 57.2M | |
| Operating Income | (28.1M) | (22.9M) | (24.8M) | (29.2M) | (49.7M) | (47.2M) | |
| Ebit | (28.1M) | (22.9M) | (26.0M) | (29.2M) | (58.4M) | (55.5M) | |
| Research Development | 23.4M | 18.2M | 19.5M | 17.6M | 12.5M | 17.3M | |
| Ebitda | (26.9M) | (22.0M) | (25.3M) | (28.5M) | (57.1M) | (54.2M) | |
| Cost Of Revenue | 940K | 934K | 702K | 654K | 3.7M | 4.4M | |
| Total Operating Expenses | 28.1M | 22.9M | 24.8M | 29.2M | 50.8M | 26.0M | |
| Income Before Tax | (25.4M) | (30.0M) | (27.1M) | (25.0M) | (60.6M) | (57.6M) | |
| Total Other Income Expense Net | 2.7M | (7.1M) | (2.3M) | 4.2M | (10.9M) | (10.4M) | |
| Net Income Applicable To Common Shares | (23.0M) | (25.4M) | (30.0M) | (27.1M) | (24.3M) | (25.6M) | |
| Net Income | (26.8M) | (30.9M) | (28.1M) | (18.9M) | (60.6M) | (57.6M) | |
| Income Tax Expense | 1.4M | 911K | 1.1M | (6.1M) | 1K | 1.1K | |
| Net Income From Continuing Ops | (25.4M) | (30.0M) | (27.1M) | (25.0M) | (60.6M) | (57.6M) | |
| Interest Income | 777K | 236K | 559K | 694K | 2.0M | 2.1M | |
| Net Interest Income | (1.1M) | (1.3M) | (447K) | (1.1M) | (162K) | (170.1K) | |
| Reconciled Depreciation | 940K | 934K | 703K | 654K | 1.4M | 886.4K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.